# Clinical References

All clinical guidelines and standards referenced by the PGx Clinical Solutions platform.

## Core Pharmacogenomics Guidelines

### CPIC (Clinical Pharmacogenetics Implementation Consortium)
- **URL:** https://cpicpgx.org/guidelines/
- **Version referenced:** Current as of February 2026
- **Used for:** Gene-drug interaction definitions, dosing recommendations, evidence levels (A/B/C)
- **Genes covered:** CYP2D6, CYP2C19, CYP2C9, CYP3A4, VKORC1, SLCO1B1, DPYD, UGT1A1, TPMT, HLA-B

### FDA Table of Pharmacogenomic Biomarkers in Drug Labeling
- **URL:** https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
- **Version referenced:** Current as of February 2026
- **Used for:** FDA label recognition flags, contraindication identification

### PharmGKB (Pharmacogenomics Knowledgebase)
- **URL:** https://www.pharmgkb.org/
- **Used for:** Supplementary drug-gene interaction data, clinical annotation levels

## Geriatric Deprescribing Standards (Planned — v0.4.0)

### 2023 AGS Beers Criteria
- **Citation:** American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081.
- **Used for:** Potentially inappropriate medication screening in patients age 65+

### STOPP/START Criteria v3
- **Citation:** O'Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. *Eur Geriatr Med*. 2023;14:625-632.
- **Used for:** Medications to stop (STOPP) and beneficial medications to start (START) in elderly

### Anticholinergic Cognitive Burden (ACB) Scale
- **Citation:** Boustani M, et al. Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*. 2008;4(3):311-320.
- **Used for:** Anticholinergic burden scoring per medication (0-3 scale)

## Renal and Hepatic Dosing

### KDIGO Clinical Practice Guidelines
- **URL:** https://kdigo.org/guidelines/
- **Used for:** eGFR-based renal staging and dose adjustment thresholds

## Oncology Gap Analysis Standards (Planned — v0.3.0)

### Shugg et al. 2022 Reference Study
- **Citation:** Shugg T, Ly RC, Rowe EJ, et al. Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. *JCO Precision Oncology*. 2022. PMID: 35201852.
- **Used for:** Methodology reference for oncology PGx gap analysis
